Drug intelligence / Profile preview

JNJ-95475939

Development stage: Phase 2
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-95475939 is an investigational drug developed by Janssen Research & Development for the treatment of moderate to severe atopic dermatitis. It acts as a dual inhibitor of the interleukin-4/interleukin-13 (IL-4/IL-13) and interleukin-31 (IL-31) pathways, which are key mediators in type 2 inflammation and the itch-scratch cycle characteristic of atopic dermatitis. By blocking these cytokines, JNJ-95475939 aims to reduce both inflammation and pruritus associated with this condition.

Targets

IL13RA2 (Interleukin-13 receptor subunit alpha 2)IL31RA (IL-31 receptor alpha)IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on JNJ-95475939.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-95475939.